Search

Your search keyword '"infusion related reaction"' showing total 3 results
Start Over Descriptor "infusion related reaction" Journal international cancer conference journal
3 results on '"infusion related reaction"'

2. Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer

Author

Hideyuki Yokokawa, Shunichi Shiozawa, Yutaka Miyano, Rie Imaizumi, Teppei Kono, Kunihiro Oyama, Hiroaki Shidei, Kazuhiko Yoshimatsu, and Yoshitomo Ito

Subjects
0301 basic medicine, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Locally advanced, Cetuximab, Case Report, Infusion related reaction, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Surgical oncology, Internal medicine, medicine, Panitumumab, Chemotherapy, business.industry, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, Premedication, business, medicine.drug
Abstract

Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodies, we experienced a successful rechallenge to Cmab after IR to Pmab. A 67-year-old female patient was scheduled for chemotherapy with mFOLFOX6 plus Pmab against unresectable advanced rectal cancer in the hope of tumor shrinkage. On the first administration of Pmab, she complained of dyspnea with shortness of breath and wheezing, even after premedication with steroids and antihistamines. Her reaction was judged as Grade 2 IR to Pmab. For the next course, we tried Cmab. No IRs were observed. Since then, she has undergone seven further courses of treatment, followed by surgical resection. The patient benefited from administration of Cmab after experiencing IR to Pmab, suggesting this treatment to be an option for patients of this type who experience IR to Pmab.

Published
2020

3. Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.

Author

Yokokawa H, Kono T, Shidei H, Oyama K, Ito Y, Imaizumi R, Miyano Y, Shiozawa S, and Yoshimatsu K

Abstract

Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodies, we experienced a successful rechallenge to Cmab after IR to Pmab. A 67-year-old female patient was scheduled for chemotherapy with mFOLFOX6 plus Pmab against unresectable advanced rectal cancer in the hope of tumor shrinkage. On the first administration of Pmab, she complained of dyspnea with shortness of breath and wheezing, even after premedication with steroids and antihistamines. Her reaction was judged as Grade 2 IR to Pmab. For the next course, we tried Cmab. No IRs were observed. Since then, she has undergone seven further courses of treatment, followed by surgical resection. The patient benefited from administration of Cmab after experiencing IR to Pmab, suggesting this treatment to be an option for patients of this type who experience IR to Pmab., Competing Interests: Conflict of interestThe authors declare that they have no conflicts of interest., (© The Author(s) 2020.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results